Abstract Details

Title Control of Both Oligodendroglioma and Multiple Sclerosis with Chemotherapy with Temozolomide: Case Report

Topic Neuro-oncology

Presentation(s) P01 - (-)

Poster/Presentation
Number 105

Objective

Background The associaition of MS and glioma is rare. There are 12 reported cases of oligodendroglioma in patients with MS. The focus of treatment is to control the tuumor, with surgery, radiation therapy and chemotherapy. Mitoxanthrone is FDA approved for treatment of patients with progressive MS but not for brain tumors, it is IV and has cardiac side- effects. Tem is an oral drug effective for treatment of oligodendroglioma.

Design/Methods Our patient is a 30 iears old lady diagnosed in 2007 with left frontal grade II oligodendroglioma. She had resection, then follow- up with MRIs. MRIs in 2010 and 2011 showed asymptomatc evolving demyelinating plaques. CSF analysis was also suggestive of MS. Because she was asymptomatic no immunemodulatory therapy was instituted. On 2/13/2012 she had second resection for small recurrence of oligodendroglioma. In March 2012 she started adjuvant chemotherapy with Tem. 150 mg/m2/day for 5 days every 28 days.

Results After 7 courses of chemotherapy with Tem she has no evidence of tumor recurrence. There are no new MS plaques on follow- up MRIs, whereas before starting Tem she had new plques appearing on each follow- up MRI scan. Tem, used to treat her brain tumor appears to control both the oligodendroglioma and MS in this patient.

Conclusions To our knowledge this is the first case repo of a patient with both oligodendroglioma and MS treated with Temozolomide with control of both diseases. This opens the potential for clinical trials with Temozolomide for patients with MS who failed immunomodulatory therapyes or patients with primary progressive MS.

Authors/Disclosures
Alexandra Flowers, MD (Hartford Hospital) PRESENTER	No disclosure on file
Franziska Di Pauli	Franziska Di Pauli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jannsen. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for horizon. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for merck. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jannsen. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Franziska Di Pauli has received research support from Roche.

��ɫ��

��ɫ��